Last reviewed · How we verify
Intravenous ribavirin
At a glance
| Generic name | Intravenous ribavirin |
|---|---|
| Sponsor | Arisan Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ARN-75039 Lassa Fever Treatment in West Africa (PHASE2)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (NA)
- Ribavirin for Hemorrhagic Fever With Renal Syndrome (PHASE2)
- The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever (PHASE3)
- Treatment of Hemorrhagic Fever With Ribavirin (PHASE2)
- Lassa Fever Clinical Course and Prognostic Factors in Nigeria
- UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous ribavirin CI brief — competitive landscape report
- Intravenous ribavirin updates RSS · CI watch RSS
- Arisan Therapeutics, Inc. portfolio CI